MBIO Stock Overview
A clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
Mustang Bio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.87 |
| 52 Week High | US$74.50 |
| 52 Week Low | US$2.40 |
| Beta | 1.72 |
| 1 Month Change | -48.29% |
| 3 Month Change | -72.39% |
| 1 Year Change | -95.41% |
| 3 Year Change | -99.52% |
| 5 Year Change | -99.88% |
| Change since IPO | -99.96% |
Recent News & Updates
Recent updates
Mustang Bio: This Horse May Gallop Still
Sep 23Is Mustang Bio, Inc. (NASDAQ:MBIO) Trading At A 46% Discount?
Aug 09
Mustang Bio: The Market Is Missing This Opportunity
May 03Will Mustang Bio (NASDAQ:MBIO) Spend Its Cash Wisely?
Dec 29Mustang Bio: Remains Underfollowed Despite Moving Closer To Pivotal Studies
Sep 14Mustang Bio (MBIO) EHA Investor Presentations - Slideshow
Jun 18Mustang Bio jumps 7% on encouraging MB-106 safety and efficacy data in blood cancers
Jun 11Checking Back In On Mustang Bio
May 26Shareholder Returns
| MBIO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 3.7% | 1.2% |
| 1Y | -95.4% | -1.0% | 23.7% |
Return vs Industry: MBIO underperformed the US Biotechs industry which returned -1% over the past year.
Return vs Market: MBIO underperformed the US Market which returned 23.7% over the past year.
Price Volatility
| MBIO volatility | |
|---|---|
| MBIO Average Weekly Movement | 19.2% |
| Biotechs Industry Average Movement | 11.0% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 18.0% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: MBIO's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: MBIO's weekly volatility has decreased from 70% to 19% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 80 | Manny Litchman | www.mustangbio.com |
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-117 and MB-217, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment.
Mustang Bio, Inc. Fundamentals Summary
| MBIO fundamental statistics | |
|---|---|
| Market cap | US$6.03m |
| Earnings (TTM) | -US$23.42m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.3x
P/E RatioIs MBIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MBIO income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$23.42m |
| Earnings | -US$23.42m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -10.94 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did MBIO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/19 05:08 |
| End of Day Share Price | 2025/02/19 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Mustang Bio, Inc. is covered by 6 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mayank Mamtani | B. Riley Securities, Inc. |
| Justin Zelin | B. Riley Securities, Inc. |
| Jonathan Aschoff | B. Riley Wealth |